Predicting tumor purity from methylation microarray data.

Area of Science:

• Genomics
• Cancer Research
• Bioinformatics

Background:

• Solid tumor samples in cancer genomics research are mixtures of cancer and normal cells.
• This cellular heterogeneity complicates data analysis and can bias findings.
• Accurate estimation of tumor purity is essential for reliable genomic analysis.

Purpose of the Study:

• To develop a method for estimating tumor purity using Illumina Infinium 450k methylation microarray data.
• To address the challenge of analyzing mixed-cell samples in cancer genomics.

Main Methods:

• Discovered a strong correlation between methylation microarray data distributions and tumor purity in cancer samples.
• Developed a novel, simple, and effective computational method for purity estimation.
• Implemented the method in a freely available software tool called InfiniumPurify.

Main Results:

• The proposed method demonstrates favorable performance in estimating tumor purity.
• Analyses using The Cancer Genome Atlas (TCGA) lung cancer data validate the method's effectiveness.
• Methylation data distributions are highly correlated with tumor purities in cancer samples.

Conclusions:

• The InfiniumPurify method provides a reliable approach for estimating tumor purity from methylation microarray data.
• This tool can improve the accuracy and reduce bias in cancer genomics studies.
• Accurate tumor purity estimation is vital for advancing cancer research and clinical applications.